Literature DB >> 29934117

Innovative invasive management without stent implantation guided by optical coherence tomography in acute coronary syndrome.

Geraud Souteyrand1, Louis Viallard2, Nicolas Combaret3, Bruno Pereira4, Guillaume Clerfond2, Guilhem Malcles2, Nicolas Barber-Chamoux2, Francesco Prati5, Pascal Motreff3.   

Abstract

BACKGROUND: A two-step strategy of invasive management without stenting, guided by optical coherence tomography (OCT), in selected patients with acute coronary syndrome (ACS), might avoid systematic stent implantation and allow medical therapy alone. AIMS: To assess the feasibility and safety of such a procedure, and to define coronary imaging characteristics in a specific population.
METHODS: This single-centre proof-of-concept study included all patients with ACS who benefited from a two-step revascularization procedure with optimal reperfusion during primary percutaneous coronary intervention followed by delayed angiography and OCT. OCT imaging determined medical therapy treatment alone without stenting in case of absence of vulnerable plaque rupture and <70% stenosis. Follow-up consisted of screening for major adverse cardiac events (MACE) at 12months.
RESULTS: Forty-six patients were included, mainly men (86.9%) and smokers (65.2%), with a mean age of 47.1years. Most cases (80.4%) were large thrombus burden lesions. Delayed angiography and OCT were performed in a median period of 6 [3-10] days. No adverse events occurred between the initial and second angiograms. Plaque rupture was detected in 39.1% of patients, plaque erosion in 54.3% and calcified nodule in 6.5%. Twenty-three patients benefited from systematic delayed OCT over a median period of 171days, showing an increase in minimal lumen area. At 12months, two patients (4.3%) presented MACE and were stented. No sudden death or myocardial infarction recurrence occurred.
CONCLUSIONS: Analysing ACS mechanisms by OCT might facilitate treatment decisions in patients with ST-segment elevation myocardial infarction managed by a two-step procedure. Conservative treatment with antithrombotic therapy without stenting seems to be a reliable option in a selected population.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Antithrombotic therapy; Imagerie par cohérence optique; Optical coherence tomography; Percutaneous coronary intervention; Plaque erosion; Plaque rupture; Rupture de plaque; Syndrome coronarien aigu; Traitement anti-thrombotique; Érosion de plaque

Mesh:

Substances:

Year:  2018        PMID: 29934117     DOI: 10.1016/j.acvd.2017.10.006

Source DB:  PubMed          Journal:  Arch Cardiovasc Dis        ISSN: 1875-2128            Impact factor:   2.340


  3 in total

1.  Safety of conservative management for non-stenotic culprit lesions in STEMI patients treated with a two-step reperfusion strategy: a SUPER-MIMI sub-study.

Authors:  Marc Bonnet; Stephanie Marliere; Victor Mathieu; Allan Tronchi; Nicolas Delarche; Mohamed Abdellaoui; Olivier Dubreuil; Ziad Boueri; Mohamed Chettibi; Geraud Souteyrand; Chloé Durier; Frederic Bouisset; Loic Belle
Journal:  Cardiovasc Diagn Ther       Date:  2022-04

2.  Optical coherence tomography guided successful treatment without stent implantation in a patient with non-ST-segment elevation myocardial infarction caused by plaque rapture: A case report.

Authors:  Fei-Fei Zhang; Yi Dang; Qing-Qing Hao; Yue-Tao Xie; Shu-Ren Li; Xiao-Yong Qi
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

3.  Clinical and Laboratory Predictors for Plaque Erosion in Patients With Acute Coronary Syndromes.

Authors:  Erika Yamamoto; Taishi Yonetsu; Tsunekazu Kakuta; Tsunenari Soeda; Yoshihiko Saito; Bryan P Yan; Osamu Kurihara; Masamichi Takano; Giampaolo Niccoli; Takumi Higuma; Shigeki Kimura; Yoshiyasu Minami; Junya Ako; Tom Adriaenssens; Niklas F Boeder; Holger M Nef; Francesco Fracassi; Tomoyo Sugiyama; Hang Lee; Filippo Crea; Takeshi Kimura; James G Fujimoto; Valentin Fuster; Ik-Kyung Jang
Journal:  J Am Heart Assoc       Date:  2019-10-23       Impact factor: 5.501

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.